Ulrich Mrowietz

Overview

Best Publications

• Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

  Lam C. Tsoi;Sarah L. Spain;Sarah L. Spain;Jo Knight;Eva Ellinghaus;Eva Ellinghaus

  1162
  Citations

• Definition of treatment goals for moderate to severe psoriasis: a European consensus

  U. Mrowietz;K. Kragballe;K. Reich;P. Spuls

  1047
  Citations

• European S3-guidelines on the systemic treatment of psoriasis vulgaris

  D Pathirana;AD Ormerod;P Saiag;Catherine Smith

  923
  Citations

• Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci

  David Ellinghaus;Luke Jostins;Sarah L. Spain;Adrian Cortes

  804
  Citations

• Quality of life of patients with keloid and hypertrophic scarring.

  Oliver Bock;Gerhard Schmid-Ott;Peter Malewski;Ulrich Mrowietz

  584
  Citations

• Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

  Kamran Ghoreschi;Peter Thomas;Susanne Breit;Martin Dugas

  557
  Citations

• Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

  C Paul;J Cather;M Gooderham;Y Poulin

  503
  Citations

• European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

  A Nast;P Gisondi;A D Ormerod;P Saiag

  496
  Citations

• Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Parallel Randomized Trial

  Alexa B. Kimball;Francisco Kerdel;David Adams;Ulrich Mrowietz

  488
  Citations

• Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation

  Henrik Wilms;Jobst Sievers;Uta Rickert;Martin Rostami-Yazdi

  466
  Citations

• European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.

  L Dubertret;U Mrowietz;Annamari Ranki;P. C. M van de Kerkhof

  444
  Citations

• Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2

  Eva Ellinghaus;David Ellinghaus;Philip E Stuart;Rajan P Nair

  439
  Citations

• European Consensus Statement on Phenotypes of Pustular Psoriasis

  A.A. Navarini;D. Burden;Francesca Capon;U. Mrowietz

  432
  Citations

• Genome-wide association analysis identifies three psoriasis susceptibility loci

  Philip E Stuart;Rajan P Nair;Eva Ellinghaus;Jun Ding

  415
  Citations

• S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

  Alexander Nast;Wolf-Henning Boehncke;Ulrich Mrowietz;Hans-Michael Ockenfels

  404
  Citations

• Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions.

  Paola Di Meglio;João H. Duarte;Helena Ahlfors;Nick D.L. Owens

  387
  Citations

• Dimethylfumarate is a potent inducer of apoptosis in human T cells.

  Felix Treumer;Kejian Zhu;Regine Gläser;Ulrich Mrowietz

  356
  Citations

• Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

  Christos C.C. Zouboulis;Véronique Del Marmol;Ulrich U. Mrowietz;Errol E.P. Prens

  337
  Citations

• Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

  Alexa B. Kimball;Francisco Kerdel;David Adams;Ulrich Mrowietz

  10
  Citations

• Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

  L. C. Tsoi;S. L. Spain;J. Knight;E. Ellinghaus

  0
  Citations